*仅供医学专业人士阅读参考益丰配资
重症肌无力领域又取得了哪些进展？
*以下内容仅供在中国大陆执业的
医疗卫生专业人士浏览。
参考文献：
[1]Gilhus NE益丰配资, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.
[2]Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.
[3]Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217
[4]Bril V, Benatar M, Andersen H; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865.
[5]Bril V, Drużdż A, Grosskreutz J; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394.
[6]Habib AA益丰配资, et al. Efficacy and Safety of Rozanolixizumab Treatment Cycles in Patients With Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 71.
[7]Vu T, et al. Responder and Minimal Symptom Expression Rates With Rozanolixizumab in Generalised Myasthenia Gravis: Final Pooled Analysis of Phase 3 Studies. MGFA 2025. Poster 206.
[8]Zabeen K, et al. Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-speciffc outcomes in MycarinG. AAN 2025. Poster P1-11-006.
[9]Wallace T, et al. Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of MycarinG. AAN 2025.
[10]Carlo Antozzi, et al. Patient preferences and experience with self-administration of rozanolixizumab in generalised myasthenia gravis: The MG0020 study. MGFA International 2025. Poster 4.
[11]Vera Bril, et al. Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study. AAN 2025. Poster P1-11-018.
医学界神经领域交流群正式开放！
加入我们吧！
[CN-RZ-2500050 有效期截止：2027年5月] 本内容仅供医疗卫生专业人士阅读，所含信息不应代替医疗卫生专业人士提供的医疗建议，也不建议医疗卫生专业人士超出说明书范围使用所涉及的药物。
*此文仅用于向医学人士提供科学信息，不代表本平台观点
*\"医学界\"力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。
广盛网提示：文章来自网络，不代表本站观点。
相关文章
沪深京指数
热点资讯
